Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Doc Stone's Bierstube und Trading Room -- Ignore unavailable to you. Want to Upgrade?

To: wolfdog2 who wrote (493)	1/23/1999 2:26:00 PM
From: wolfdog2	Read Replies (1) \| Respond to of 638

COB Frank,please add COB to the model portfolio. Although the stock has doubled in the past few weeks, I think there's a lot more to come. The stock ran up on, I think, the rumor published by Fahnstock (so I'm told) that they will be adding a new distribution partner for one of their lead drugs, Crinone 8%. I expect a lot of news out of the company over the next week, including an announcement of new financing, additions to management. Also there will likely be a licensing agreement announced for their andropause drug. Later in the quarter, there will, hopefully be a partnership agreement put in place to develop and market terbutaline, which potentially could be a large seller. And of course, there is always the possibility that an additional distribution will be announced for Crinone 8%. COB's annual meeting is scheduled for this coming Thursday in NYC. I expect that the company will make at least one announcement before the meeting and probably one or more at the meeting itself. The stock closed Friday at 5 7/16. My target for this year is 9. If things really fall into place, I think the stock could double from their by the end of next year. Also I hope you added CSON at the time I wrote it up here. It was ~3 7/8 at the time. It's now trading around six. I think this could very well be the year for biotech stocks. Major pharmas are pricey and I expect some of that money to flow out of them and into biotechs, especially since there will be a large number of new drugs approved this year, which should boost interest.